The dilated state typically persists for 4-6 hours, though the exact duration varies with individual response and the number of drops administered. Vision usually returns to normal once the drug effect wanes.
Mydriacyl is supplied in a transparent or amber-coloured plastic bottle containing a 1 % tropicamide solution. The label includes the brand name, concentration, dosage form (“eye drops”), and a batch number.
It is advisable to avoid driving, operating machinery, or performing tasks requiring clear near vision until the visual blurring and photophobia resolve, usually a few hours after administration.
Tropicamide is classified as Category B in the UK, indicating no evidence of risk in animal studies and insufficient human data. Use should be limited to situations where the clinical benefit outweighs any potential risk, and only under medical supervision.
Concurrent use of other mydriatic agents (e.g., phenylephrine) may produce additive dilation and increase intra-ocular pressure. Other topical ocular medications should be spaced by at least 5 minutes to prevent dilution or altered absorption.
Yes. Contact lenses should be removed prior to drop administration to avoid trapping the solution on the lens surface, which could reduce efficacy and increase irritation.
Severe pain, accompanied by halos, headache, or visual loss, may signal acute angle-closure glaucoma. Seek emergency ophthalmic care immediately.
Routine use in children younger than two years is not recommended due to limited safety data. If dilation is essential, it should be performed by a pediatric ophthalmologist with careful monitoring.
No. Tropicamide’s effects are temporary; there is no permanent alteration of pupil size or visual acuity when used as directed.
Discard the bottle according to local pharmacy or waste-disposal guidelines after the 28-day usage period or when the expiry date is reached. Do not flush the solution down the drain.
Mydriacyl is a prescription eye-drop product that contains tropicamide as its sole active ingredient. It is supplied as a sterile 1 % solution in a single-use or multi-dose bottle. The medication belongs to the eye-care therapeutic class and is regulated in the United Kingdom by the Medicines and Healthcare products Regulatory Agency (MHRA). Mydriacyl is a muscarinic antagonist used primarily to produce temporary pupil dilation (mydriasis) and paralysis of the accommodation reflex (cycloplegia) for diagnostic ophthalmic examinations and certain therapeutic procedures.
Tropicamide works by competitively blocking muscarinic (M₃) receptors on the smooth muscle of the iris sphincter and the ciliary body. By inhibiting these receptors, the drug prevents acetylcholine-mediated contraction, leading to relaxation of the iris sphincter muscle and consequent pupil dilation. Simultaneously, reduced ciliary muscle tone produces cycloplegia, temporarily eliminating the eye’s ability to focus on near objects. The onset of dilation typically occurs within 15-30 minutes after a single drop, peaks around 30-60 minutes, and subsides over 4-6 hours as the drug is metabolised and cleared from the ocular surface.
Mydriacyl (tropicamide 1 %) is approved in the UK for the following indications:
These uses are supported by the product’s pharmacodynamic profile and extensive clinical experience in ophthalmology.
This article provides educational information about Mydriacyl and is not a substitute for professional medical advice. Treatment decisions, including the use of unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
